-

ReCode Therapeutics to Present at September Investor Conferences

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage company powering the next wave of genetic medicines, today announced that Company management will participate in the following upcoming investor conferences in September 2023:

Morgan Stanley Global Healthcare Conference:
Format: Company Presentation
Date: September 12, 2023
Time: 12:55 p.m. ET
Presenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics
Location: New York, NY

Jefferies Cell & Genetic Medicine Summit
Format: Company Presentation
Date: September 26, 2023
Time: 10:30 a.m. ET
Presenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics
Location: New York, NY

BMO Biopharma Spotlight Series: Latest Advances in Genome/Epigenome Editing
Format: Panel Discussion - Novel Approaches in Gene Editing and Delivery
Date: September 26, 2023
Time: 2:30 p.m. ET
Presenter: Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics
Location: Virtual

About ReCode Therapeutics

ReCode Therapeutics is a clinical-stage company powering the next wave of genetic medicines. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode’s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. In 2022, ReCode was named among Fierce Biotech’s “Fierce 15” as one of the most promising early-stage biotechnology companies in the industry and was described by Nature as one of the “Seven Technologies to Watch in 2022” for its SORT LNP platform. For more information, visit www.recodetx.com and follow us on LinkedIn.

Contacts

Investor Contact:
Anne Marie Fields
Stern IR
annemarie.fields@sternir.com
IR@recodetx.com

Media Contact:

Erica Jefferson
ReCode Therapeutics
ejefferson@recodetx.com
650- 629-7965

Tara Cooper
The Grace Communication Group
tara@gracegroup.us
650-303-7306

Industry:

ReCode Therapeutics

Release Versions
English

Contacts

Investor Contact:
Anne Marie Fields
Stern IR
annemarie.fields@sternir.com
IR@recodetx.com

Media Contact:

Erica Jefferson
ReCode Therapeutics
ejefferson@recodetx.com
650- 629-7965

Tara Cooper
The Grace Communication Group
tara@gracegroup.us
650-303-7306

More News From ReCode Therapeutics

ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the initiation of Part 3 of its ongoing Phase 2 clinical trial evaluating RCT2100, an investigational inhaled CFTR mRNA therapy, in combination with ivacaftor in people with cystic fibrosis (CF). Clinical sites...

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced the close of over $29 million in additional financing. The company also reported expanded support from the Cystic Fibrosis Foundation (CF Foundation) and a new research collaboration with Praxis Precision Medicines, Inc. (NASDAQ: PRAX). “With continued support from organizations like t...

ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment of Cystic Fibrosis

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RCT2100, a novel, investigational mRNA therapy being developed to treat cystic fibrosis (CF). CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Altho...
Back to Newsroom